Merck 2014 Annual Report Download - page 165

160 CORPORATE GOVERNANCE → Statement on Corporate Governance
On January 26, 2014 a new election of the Board of Partners was
held. The Board of Partners now consists of the following members:
Member
Memberships of
(a) other statutory supervisory boards and
(b) comparable German and foreign supervisory bodies of corporations
Johannes Baillou
Vienna, Austria, Vice Chairman of the Executive Board
and General Partner of E. Merck KG, Darmstadt, Germany, Chairman (a) – Merck KGaA, Darmstadt, Germany (until May 9, 2014)
Frank Stangenberg-Haverkamp
Darmstadt, Chairman of the Executive Board
and General Partner of E. Merck KG, Darmstadt, Germany
(a) – Fortas AG, Rösrath (Chairman)
(b) – Oras Invest Ltd, Helsinki, Finland
– Travel Asset Group Ltd., London, United Kingdom (Chairman)
Wolfgang Büchele
Römerberg, Chairman of the Executive Board of Linde AG, Munich
(a) – Merck KGaA, Darmstadt, Germany
(b) – Kemira Oyi, Helsinki, Finland
Siegfried Karjetta
Darmstadt, Physician (a) – Merck KGaA, Darmstadt, Germany (since May 9, 2014)
Albrecht Merck
Schriesheim, Commercial Director of the Castel Peter Winery,
Bad Dürkheim (a) – Merck KGaA, Darmstadt, Germany
Helga Rübsamen-Schaeff
Langenburg, Managing Director of AiCuris GmbH & Co. KG, Wuppertal
(a) – Merck KGaA, Darmstadt, Germany (since May 9, 2014)
– 4SC AG, Martinsried (since January 2, 2015)
Gregor Schulz
Umkirch, Pediatrician
(a) – Merck KGaA, Darmstadt, Germany (since May 9, 2014)
(b) – Biotest US Corporation, Boca Raton, FL, USA (until December 31, 2014)
– Biotest Pharmaceuticals Corporation, Boca Raton, FL, USA
 (until December 31, 2014)
– Biotest (UK) Ltd., Solihull, United Kingdom (until December 31, 2014)
– Biotest Seralc NV, Evere, Belgium (until December 31, 2014)
Theo Siegert
Düsseldorf, Managing Partner of
de Haen Carstanjen & Söhne, Düsseldorf
(a) – Merck KGaA, Darmstadt, Germany
– E.ON SE, Düsseldorf
– Henkel AG & Co KGaA, Düsseldorf
(b) – DKSH Holding Ltd., Zurich, Switzerland
Tobias Thelen
Munich, Managing Partner of
Altmann Analytik GmbH & Co. KG, Munich (a) – Merck KGaA, Darmstadt, Germany (since May 9, 2014)
The Board of Partners supervises the Executive Board in its man-
agement of the company. It informs itself about the business matters
o
f Merck KGaA, Darmstadt, Germany, a nd may inspect and exam-
ine the company’s accounts and other business documents, and the
assets for this purpose. According to Article 13 (4) of the Articles of
Association of
Merck KGaA, Darmstadt, Germany, th e Executive
Board requires the
approval of E. Merck KG, Darmstadt, Germany,
for transac
tions that are beyond the scope of the Group’s ordinary
business activities. For such transactions to be approved, approval
must first be obtained from the Board of Partne
rs of E. Merck KG,
Darmstadt, Germany. The Board of Partner
s convenes as and when
necessary; however, it meets at least four times a year. The members
of the Executive Board
of Merck KGaA, Darmstadt, Germany, a re
invited to all meetings of the Board of Partners, unless the Board of
Partners resolves otherwise in individual cases. The members of
the Board of Partners may convene a joint meeting with the Super -
visory Board of Merck KGaA, Darmstadt, Germany, if so agreed by
the chairmen of the two boards.
The Board of Partners may confer the responsibility for indi-
vidual duties to committees. Currently the Board of Partners has
three committees in place: the Personnel Committee, the Finance
Committee, and the Research and Development Committee.
Personnel Committee
The Personnel Committee has four members. Up until January26,
2014 these were: Frank Stangenberg-Haverkamp (Chairman), Jon
Baumhauer, Rolf Krebs and Theo Siegert.
Since January26, 2014,
the Personnel Committee comprises Frank Stangenberg- Haverkamp
(Chairman), Johannes Baillou, Wolfgang Büchele and Theo Siegert.